Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
Rise of vaccine distrust - why more of us are questioning jabs
And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...
Don’t Call Kennedy a Vaccine Skeptic. Call Him What He Is: A Cynic.
Mr. Kennedy, on the other hand, is a vaccine cynic, failing to accept studies that refute his beliefs. He claims that the ...
RFK Jr. says he’ll keep making money on anti-vaccine lawsuits while in office
The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.
Milwaukee Journal Sentinel18d
PolitiFact: Yes, there have been placebo-controlled studies on childhood vaccines
Asked on WISN's "Upfront" on Nov. 17 about his praise for Kennedy and false claims about vaccines causing autism, Johnson ...
Exclusive: Kennedy played key role in Gardasil vaccine case against Merck
Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Milwaukee Journal Sentinel21d
Fact check: Yes, there have been placebo-controlled studies on childhood vaccines
Even by that narrower definition, though, there are some childhood vaccines that have gone through trials in which a saline placebo was used, making Johnson’s claim inaccurate. Sometimes ...
Cautious Hold Recommendation for Johnson & Johnson Amid ITCI Acquisition Concerns and Market Challenges
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...
Hosted on MSN1d
Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat
Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...